Florida Man Develops Bladder Cancer as Result of Taking Actos, Alleges Lawsuit Filed by Parker Waichman LLP

Parker Waichman LLP has filed a lawsuit on behalf of a Florida man alleging that he developed bladder cancer as a result of taking Actos (pioglitazone). Actos is a Type 2 diabetes medication manufactured by Takeda Pharmaceuticals; several studies, including research reviewed by the U.S. Food and Drug Administration, indicate that it is associated with an increased risk of bladder cancer.

New York, NY (PRWEB) June 24, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Florida man who developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23, 2013 in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1236). It is one of thousands of cases that have been filed into the multidistrict litigation (MDL) entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff took Actos to treat his Type 2 diabetes from January 2002 to April 2005, when he was diagnosed with bladder cancer. The lawsuit alleges that his bladder cancer was due to the side effects of Actos. Additionally, the suit alleges that the Defendants knew about the risk of bladder cancer but did not disclose this information to consumers in order to protect financial interests. The Plaintiff alleges that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer and announced that the label would be updated to reflect this risk. This warning was based on an ongoing 10-year study by Kaiser Permanente. (http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm)

Several studies support the link between Actos and bladder cancer. Last May, a study in the British Medical Journal found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal found that patients taking the medication were 22 percent more likely to get bladder cancer. (http://www.bmj.com/content/344/bmj.e3645) (http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102)

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn Contact's Google Plus